Cellular Dynamics International Receives $30,000,000 Series B Funding Round

  • Feed Type
  • Date
  • Company Name
    Cellular Dynamics International
  • Mailing Address
    525 Science Drive Madison, WI 53711
  • Company Description
    Cellular Dynamics was founded by three world-class scientists in cardiac ion channel models, hES cells, and iPS cells to provide cardiac toxicity drug testing services, including GLP and non-GLP hERG electrophysiological assays as well as action potential and cytotoxicity screens using hES-cell derived cardiomycytes.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    This financing enables the company to launch new iCell® iPSC lines as well as iCell Endothelial Cells, iCell Neurons, and iCell Hepatocytes lines for biomedical and pharmaceutical drug development and safety research, as well as continue to increase production capacity for its iCell Cardiomyocytes. CDI also plans to continue to rapidly expand its commercial organization to meet the growing demand for these iPSC-based products.
  • M&A Terms
  • Venture Investor
    Tactics II Investments
  • Venture Investor
    Equity Group Investments
  • Venture Investor

Trending on Xconomy